CTOs on the Move

Zentaris

www.zentaris.com

 
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zentaris.com
  • 315 Sigma Drive
    Summerville, QC CAN 29486
  • Phone: 843.900.3223

Executives

Name Title Contact Details

Funding

Zentaris raised $29.7M on 02/17/2021

Similar Companies

VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health for US, European and other world markets.

MEM SLOAN KETTERING CANCER C

MEM SLOAN KETTERING CANCER C is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GL Sciences

GL Sciences is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Azur Pharma

Azur Pharma is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.